The complexity of contraceptives: Understanding their impact on genital immune cells and vaginal microbiota

AIDS

Volumn 27, Issue SUIPPL.1, 2013, Pages

  Achilles, Sharon L ^a,b   Hillier, Sharon L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

genital tract immune cells; HIV risk; hormonal contraception; progestins; vaginal microbiota; vaginal microflora

Indexed keywords

CONTRACEPTIVE AGENT; ETONOGESTREL; GESTAGEN; GLUCOCORTICOID RECEPTOR; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; METRONIDAZOLE; NORELGESTROMIN; NORETHISTERONE ENANTATE; ORAL CONTRACEPTIVE AGENT;

ADAPTIVE IMMUNITY; ARTICLE; CELL POPULATION; CONCENTRATION (PARAMETERS); CONTRACEPTION; GENITAL SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; PRIORITY JOURNAL; SEXUAL TRANSMISSION; VAGINA FLORA; VAGINITIS;

CONTRACEPTIVE AGENTS; FEMALE; GENITALIA, FEMALE; HUMANS; MICROBIOTA;

EID: 84885664531     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000058     Document Type: Article

References (90)

1. United Nations Millennium Development Goals Report. New York; 2011.
2. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2012; 12:19-26.
3. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464:217-223.
4. Kaul R, Pettengell C, Sheth PM, Sunderji S, Biringer A, MacDonald K, et al. The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. J Reprod Immunol 2008; 77:32-40.
5. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929.
6. Hladik F, Doncel GF. Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities. Antiviral Res ; 88:S3-S9.
7. Heffron R, Donnell D, Rees H, Celum C, Were E, Mugo N, et al. Hormonal contraceptive use and risk of HIV-1 transmission: a prospective cohort analysis. 6th International AIDS Society Conference. Rome, Italy; 2011.
8. Miller L, Patton DL, Meier A, Thwin SS, Hooton TM, Eschenbach DA. Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstet Gynecol 2000; 96:431-439.
9. Mauck CK, Callahan MM, Baker J, Arbogast K, Veazey R, Stock R, et al. The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy. Contraception 1999; 60:15-24.
10. Bahamondes L, Trevisan M, Andrade L, Marchi NM, Castro S, Diaz J, et al. The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera. Contraception 2000; 62:23-27.
11. Chandra N, Thurman AR, Anderson S, Cunningham TD, Yousefieh N, Mauck C, et al. Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues. AIDS Res Hum Retroviruses 2013; 29:592-601.
12. Barbone F, Austin H, Louv WC, Alexander WJ. A follow-up study of methods of contraception, sexual activity, and rates of trichomoniasis, candidiasis, and bacterial vaginosis. Am J Obstet Gynecol 1990; 163:510-514.
13. Riggs M, Klebanoff M, Nansel T, Zhang J, Schwebke J, Andrews W. Longitudinal association between hormonal contraceptives and bacterial vaginosis in women of reproductive age. Sex Transm Dis 2007; 34:954-959.
14. Rifkin SB, Smith MR, Brotman RM, Gindi RM, Erbelding EJ. Hormonal contraception and risk of bacterial vaginosis diagnosis in an observational study of women attending STD clinics in Baltimore, MD. Contraception 2009; 80:63-67.
15. Madden T, Grentzer JM, Secura GM, Allsworth JE, Peipert JF. Risk of bacterial vaginosis in users of the intrauterine device: a longitudinal study. Sex Transm Dis 2012; 39:217-222.
16. Bradshaw CS, Vodstrcil LA, Hocking JS, Law M, Pirotta M, Garland SM, et al. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis 2013; 56:777-786.
17. Baeten JM, Nyange PM, Richardson BA, Lavreys L, Chohan B, Martin HL Jr, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol 2001; 185:380-385.
18. Kontula K, Paavonen T, Luukkainen T, Andersson LC. Binding of progestins to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes. Biochem Pharmacol 1983; 32:1511-1518.
19. Chomont N, Gresenguet G, Levy M, Hocini H, Becquart P, Matta M, et al. Detection of Y chromosome DNA as evidence of semen in cervicovaginal secretions of sexually active women. Clin Diagn Lab Immunol 2001; 8:955-958.
20. Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids 2011; 76:636-652.
21. Huijbregts RP, Helton ES, Michel KG, Sabbaj S, Richter HE, Goepfert PA, et al. Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptiveimmunemechanisms. Endocrinology 2013; 154:1282-1295.
22. Rottman JB, Ganley KP, Williams K, Wu L, Mackay CR, Ringler DJ. Cellular localization of the chemokine receptor CCR5. Correlation to cellular targets of HIV-1 infection. Am J Pathol 1997; 151:1341-1351.
23. Patterson BK, Landay A, Andersson J, Brown C, Behbahani H, Jiyamapa D, et al. Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am J Pathol 1998; 153:481-490.
24. Yeaman GR, Howell AL, Weldon S, Demian DJ, Collins JE, O'Connell DM, et al. Human immunodeficiency virus receptor and coreceptor expression on human uterine epithelial cells: regulation of expression during the menstrual cycle and implications for human immunodeficiency virus infection. Immunology 2003; 109:137-146.
25. Prakash M, Kapembwa MS, Gotch F, Patterson S. Oral contraceptive use induces upregulation of the CCR5 chemokine receptor on CD4(R) T cells in the cervical epithelium of healthy women. J Reprod Immunol 2002; 54:117-131.
26. Sheffield JS, Wendel GD Jr, McIntire DD, Norgard MV. The effect of progesterone levels and pregnancy on HIV-1 coreceptor expression. Reprod Sci 2009; 16:20-31.
27. Morrison CS, Chen PL, Kwok C, Richardson BA, Chipato T, Mugerwa R, et al. Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS 2010; 24:1778-1781.
28. Gupta P, Collins KB, Ratner D, Watkins S, Naus GJ, Landers DV, et al. Memory CD4(R) T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system. J Virol 2002; 76:9868-9876.
29. Inoue T, Kanzaki H, Imai K, Narukawa S, Katsuragawa H, Watanabe H, et al. Progesterone stimulates the induction of human endometrial CD56R lymphocytes in an in vitro culture system. J Clin Endocrinol Metab 1996; 81:1502-1507.
30. Wieser F, Hosmann J, Tschugguel W, Czerwenka K, Sedivy R, Huber JC. Progesterone increases the number of Langerhans cells in human vaginal epithelium. Fertil Steril 2001; 75:1234-1235.
31. Souza SS, Castro FA, Mendonca HC, Palma PV, Morais FR, Ferriani RA, et al. Influence of menstrual cycle on NK activity. J Reprod Immunol 2001; 50:151-159.
32. Hild-Petito S, Veazey RS, Larner JM, Reel JR, Blye RP. Effects of two progestin-only contraceptives, Depo-Provera and Norplant-II, on the vaginal epithelium of rhesus monkeys. Aids Res Hum Retroviruses 1998; 14:S125-S130.
33. Smith SM, Baskin GB, Marx PA. Estrogen protects against vaginal transmission of simian immunodeficiency virus. J Infect Dis 2000; 182:708-715.
34. Li QS, Duan LJ, Estes JD, Ma ZM, Rourke T, Wang YC, et al. Peak SIV replication in resting memory CD4(R) T cells depletes gut lamina propria CD4(R) T cells. Nature 2005; 434:1148-1152.
35. Saba E, Grivel JC, Vanpouille C, Brichacek B, Fitzgerald W, Margolis L, et al. HIV-1 sexual transmission: early events of HIV-1 infection of human cervico-vaginal tissue in an optimized ex vivo model. Mucosal Immunol 2010; 3:280-290.
36. Kader M, Wang X, Piatak M, Lifson J, Roederer M, Veazey R, et al. Alpha4(R)beta7(hi)CD4(R) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol 2009; 2:439-449.
37. Hladik F, Lentz G, Delpit E, McElroy A, McElrath MJ. Coexpression of CCR5 and IL-2 in human genital but not blood T cells: implications for the ontogeny of the CCR5R Th1 phenotype. J Immunol 1999; 163:2306-2313.
38. Gray RH, Li X, Kigozi G, Serwadda D, Brahmbhatt H, Wabwire-Mangen F, et al. Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet 2005; 366:1182-1188.
39. Morrison CS, Wang J, Van Der Pol B, Padian N, Salata RA, Richardson BA. Pregnancy and the risk of HIV-1 acquisition among women in Uganda and Zimbabwe. AIDS 2007; 21: 1027-1034.
40. Reid SE, Dai JY, Wang J, Sichalwe BN, Akpomiemie G, Cowan FM, et al. Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr 2010; 53:606-613.
41. Hel Z, Stringer E, Mestecky J. Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev 2010; 31:79-97.
42. Beagley KW, Gockel CM. Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. FEMS Immunol Med Microbiol 2003; 38:13-22.
43. Ghanem KG, Shah N, Klein RS, Mayer KH, Sobel JD, Warren DL, et al. Influence of sex hormones, HIV status, and concomitant sexually transmitted infection on cervicovaginal inflammation. J Infect Dis 2005; 191:358-366.
44. Clemens LE, Siiteri PK, Stites DP. Mechanism of immunosuppression of progesterone on maternal lymphocyte activation during pregnancy. J Immunol 1979; 122:1978-1985.
45. White HD, Crassi KM, Givan AL, Stern JE, Gonzalez JL, Memoli VA, et al. CD3R CD8R CTL activity within the human female reproductive tract: influence of stage of the menstrual cycle and menopause. J Immunol 1997; 158:3017-3027.
46. Stern JE, Givan AL, Gonzalez JL, Harper DM, White HD, Wira CR. Leukocytes in the cervix: a quantitative evaluation of cervicitis. Obstet Gynecol 1998; 91:987-992.
47. Givan AL, White HD, Stern JE, Colby E, Gosselin EJ, Guyre PM, et al. Flow cytometric analysis of leukocytes in the human female reproductive tract: comparison of fallopian tube, uterus, cervix, and vagina. Am J Reprod Immunol 1997; 38: 350-359.
48. White HD, Prabhala RH, Humphrey SL, Crassi KM, Richardson JM, Wira CR. A method for the dispersal and characterization of leukocytes from the human female reproductive tract. Am J Reprod Immunol 2000; 44:96-103.
49. Cohen CR, Moscicki AB, Scott ME, Ma Y, Shiboski S, Bukusi E, et al. Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa. AIDS 2010; 24:2069-2074.
50. Pudney J, Quayle AJ, Anderson DJ. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod 2005; 73:1253-1263.
51. Kaldensjo T, Petersson P, Tolf A, Morgan G, Broliden K, Hirbod T. Detection of intraepithelial and stromal langerin and CCR5 positive cells in the human endometrium: potential targets for HIV infection. PLoS ONE 2011; 6:e21344.
52. Novak RM, Metch B, Buchbinder S, Cabello R, Donastorg Y, Figoroa JP, et al. Risk behavior among women enrolled in a randomized controlled efficacy trial of an adenoviral vector vaccine to prevent HIV acquisition. AIDS 2013; 27:1763-1770.
53. Tibaldi C, Cappello N, Latino MA, Masuelli G, Marini S, Benedetto C. Vaginal and endocervical microorganisms in symptomatic and asymptomatic nonpregnant females: risk factors and rates of occurrence. Clin Microbiol Infect 2009; 15:670-679.
54. Pettifor A, Delany S, Kleinschmidt I, Miller WC, Atashili J, Rees H. Use of injectable progestin contraception and risk of STI among South African women. Contraception 2009; 80:555-560.
55. McClelland RS, Richardson BA, Graham SM, Masese LN, Gitau R, Lavreys L, et al. A prospective study of risk factors for bacterial vaginosis in HIV-1-seronegative African women. Sex Transm Dis 2008; 35:617-623.
56. Sewankambo N, Gray RH, Wawer MJ, Paxton L, McNaim D, Wabwire-Mangen F, et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 1997; 350:546-550.
57. Cohen CR, Duerr A, Pruithithada N, Rugpao S, Hillier S, Garcia P, et al. Bacterial vaginosis and HIV seroprevalence among female commercial sex workers in Chiang Mai, Thailand. AIDS 1995; 9:1093-1097.
58. Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 2008; 22:1493-1501.
59. Serwadda D, Gray RH, Sewankambo NK, Wabwire-Mangen F, Chen MZ, Quinn TC, et al. Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. J Infect Dis 2003; 188:1492-1497.
60. Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004; 35:435-445.
61. Auvert B, Marais D, Lissouba P, Zarca K, Ramjee G, Williamson A-L. High-risk human papillomavirus is associated with HIV acquisition among south african female sex workers. Infect Dis Obstet Gynecol 2011; 2011:.
62. MasCasullo V, Fam E, Keller MJ, Herold BC. Role of mucosal immunity in preventing genital herpes infection. Viral Immunol 2005; 18:595-606.
63. Morrison CS, Turner AN, Jones LB. Highly effective contraception and acquisition of HIV and other sexually transmitted infections. Best Pract Res Clin Obstet Gynaecol 2009; 23:263-284.
64. Srinivasan S, Hoffman NG, Morgan MT, Matsen FA, Fiedler TL, Hall RW, et al. Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. PLoS ONE 2012; 7:e37818.
65. Low N, Chersich MF, Schmidlin K, Egger M, Francis SC, van de Wijgert JH, et al. Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data metaanalysis. PLoS Med 2011; 8:e1000416.
66. van de Wijgert JH, Morrison CS, Brown J, Kwok C, Van Der Pol B, Chipato T, et al. Disentangling contributions of reproductive tract infections to HIV acquisition in African Women. Sex Transm Dis 2009; 36:357-364.
67. Roccio M, Gardella B, Maserati R, Zara F, Iacobone D, Spinillo A. Low-dose combined oral contraceptive and cervicovaginal shedding of human immunodeficiency virus. Contraception 2011; 83:564-570.
68. Coleman JS, Hitti J, Bukusi EA, Mwachari C, Muliro A, Nguti R, et al. Infectious correlates of HIV-1 shedding in the female upper and lower genital tracts. AIDS 2007; 21:755-759.
69. Cohen CR, Lingappa JR, Baeten JM, Ngayo MO, Spiegel CA, Hong T, et al. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med 2012; 9: e1001251.
70. Rebbapragada A, Howe K, Wachihi C, Pettengell C, Sunderji S, Huibner S, et al. Bacterial vaginosis in HIV-infected women induces reversible alterations in the cervical immune environment. J Acquir Immune Defic Syndr 2008; 49:520-522.
71. Cherpes TL, Hillier SL, Meyn LA, Busch JL, Krohn MA. A delicate balance: risk factors for acquisition of bacterial vaginosis include sexual activity, absence of hydrogen peroxide-producing lactobacilli, black race, and positive herpes simplex virus type 2 serology. Sex Transm Dis 2008; 35:78-83.
72. Nagot N, Ouedraogo A, Defer MC, Vallo R, Mayaud P, Van de Perre P. Association between bacterial vaginosis and Herpes simplex virus type-2 infection: implications for HIV acquisition studies. Sex Transm Infect 2007; 83:365-368.
73. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and metaanalysis of longitudinal studies. AIDS 2006; 20:73-83.
74. Watts DH, Fazzari M, Minkoff H, Hillier SL, Sha B, Glesby M, et al. Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis 2005; 191:1129-1139.
75. Mitchell CM, Balkus J, Agnew KJ, Cohn S, Luque A, Lawler R, et al. Bacterial vaginosis, not HIV, is primarily responsible for increased vaginal concentrations of proinflammatory cytokines. AIDS Res Hum Retroviruses 2008; 24:667-671.
76. Yudin MH, Landers DV, Meyn L, Hillier SL. Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial vaginosis during pregnancy: a randomized trial. Obstet Gynecol 2003; 102:527-534.
77. Cherpes TL, Marrazzo JM, Cosentino LA, Meyn LA, Murray PJ, Hillier SL. Hormonal contraceptive use modulates the local inflammatory response to bacterial vaginosis. Sex Transm Infect 2008; 84:57-61.
78. Cauci S, Guaschino S, De Aloysio D, Driussi S, De Santo D, Penacchioni P, et al. Interrelationships of interleukin-8 with interleukin-1beta and neutrophils in vaginal fluid of healthy and bacterial vaginosis positive women. Mol Hum Reprod 2003; 9:53-58.
79. Hedges SR, Barrientes F, Desmond RA, Schwebke JR. Local and systemic cytokine levels in relation to changes in vaginal flora. J Infect Dis 2006; 193:556-562.
80. Losikoff P, Fichorova R, Snyder B, Rodriguez I, Cu-Uvin S, Harwell J, et al. Genital tract interleukin-8 but not interleukin-1beta or interleukin-6 concentration is associated with bacterial vaginosis and its clearance in HIV-infected and HIV-uninfected women. Infect Dis Obstet Gynecol 2007; 2007:92307.
81. Shoubnikova M, Hellberg D, Nilsson S, Mardh PA. Contraceptive use in women with bacterial vaginosis. Contraception 1997; 55:355-358.
82. Calzolari E, Masciangelo R, Milite V, Verteramo R. Bacterial vaginosis and contraceptive methods. Int J Gynaecol Obstet 2000; 70:341-346.
83. Holzman C, Leventhal JM, Qiu H, Jones NM, Wang J. Factors linked to bacterial vaginosis in nonpregnant women. Am J Public Health 2001; 91:1664-1670.
84. Hutchinson KB, Kip KE, Ness RB. Condom use and its association with bacterial vaginosis and bacterial vaginosis-associated vaginal microflora. Epidemiology 2007; 18: 702-708.
85. Gupta K, Hillier SL, Hooton TM, Roberts PL, Stamm WE. Effects of contraceptive method on the vaginal microbial flora: a prospective evaluation. J Infect Dis 2000; 181:595-601.
86. Eschenbach DA, Patton DL, Meier A, Thwin SS, Aura J, Stapleton A, et al. Effects of oral contraceptive pill use on vaginal flora and vaginal epithelium. Contraception 2000; 62:107-112.
87. Veres S, Miller L, Burington B. A comparison between the vaginal ring and oral contraceptives. Obstet Gynecol 2004; 104:555-563.
88. Creinin MD, Meyn LA, Borgatta L, Barnhart K, Jensen J, Burke AE, et al. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstet Gynecol 2008; 111:267-277.
89. Garza-Flores J, Moraks del Olmo A, Fuziwara JL, Figueroa JG, Alonso A, Monroy J, et al. Introduction of cyclofem once-amonth injectable contraceptive in Mexico. Contraception 1998; 58:7-12.
90. Beigi RH, Meyn LA, Moore DM, Krohn MA, Hillier SL. Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstet Gynecol 2004; 104:926-930.